Cargando…

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

CXCR4 is a G-protein-coupled receptor that mediates recruitment of blood cells toward its ligand SDF-1. In cancer, high CXCR4 expression is frequently associated with tumor dissemination and poor prognosis. We evaluated the novel CXCR4 probe [(68)Ga]Pentixafor for in vivo mapping of CXCR4 expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Philipp-Abbrederis, Kathrin, Herrmann, Ken, Knop, Stefan, Schottelius, Margret, Eiber, Matthias, Lückerath, Katharina, Pietschmann, Elke, Habringer, Stefan, Gerngroß, Carlos, Franke, Katharina, Rudelius, Martina, Schirbel, Andreas, Lapa, Constantin, Schwamborn, Kristina, Steidle, Sabine, Hartmann, Elena, Rosenwald, Andreas, Kropf, Saskia, Beer, Ambros J, Peschel, Christian, Einsele, Hermann, Buck, Andreas K, Schwaiger, Markus, Götze, Katharina, Wester, Hans-Jürgen, Keller, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403048/ https://www.ncbi.nlm.nih.gov/pubmed/25736399 http://dx.doi.org/10.15252/emmm.201404698

Ejemplares similares

CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma
por: Lapa, Constantin, et al.
Publicado: (2017)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
por: Habringer, Stefan, et al.
Publicado: (2018)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

Targeting Paraprotein Biosynthesis for Non-Invasive Characterization of Myeloma Biology
por: Lückerath, Katharina, et al.
Publicado: (2013)

Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
por: Wester, Hans Jürgen, et al.
Publicado: (2015)

(11)C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement
por: Lapa, Constantin, et al.
Publicado: (2016)

(18)FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation
por: Lapa, Constantin, et al.
Publicado: (2014)

(11)C-Methionine-PET: A novel and sensitive tool for monitoring of early response to treatment in multiple myeloma
por: Lückerath, Katharina, et al.
Publicado: (2015)

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2014)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model
por: Poschenrieder, Andreas, et al.
Publicado: (2017)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Reduced splenic uptake on (68)Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis
por: Kraus, Sabrina, et al.
Publicado: (2022)

(11)C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions
por: Lapa, Constantin, et al.
Publicado: (2017)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

Response assessment with the CXCR4-directed positron emission tomography tracer [(68)Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities
por: Herhaus, Peter, et al.
Publicado: (2017)

Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma
por: Jacobs, Laura, et al.
Publicado: (2017)

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

Influence of corticosteroid treatment on CXCR4 expression in DLBCL
por: Martin, Sebastian, et al.
Publicado: (2023)

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
por: Werner, Rudolf A., et al.
Publicado: (2017)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
por: Weineisen, Martina, et al.
Publicado: (2014)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

[(99m)Tc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience
por: Konrad, Matthias, et al.
Publicado: (2023)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

Non-Invasive Bioluminescence Imaging to Monitor the Immunological Control of a Plasmablastic Lymphoma-Like B Cell Neoplasia after Hematopoietic Cell Transplantation
por: Chopra, Martin, et al.
Publicado: (2013)

In Vivo Targeting of CXCR4—New Horizons
por: Schottelius, Margret, et al.
Publicado: (2021)

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
por: Garz, Anne-Kathrin, et al.
Publicado: (2017)

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
por: Wirtz, Martina, et al.
Publicado: (2018)

Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
por: Heidegger, Simon, et al.
Publicado: (2014)

Novel molecular subgroups within the context of receptor tyrosine kinase and adhesion signalling in multiple myeloma
por: Leich, Ellen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c6ut9ksoemvli8uqgnkbcnqtbq